

TREATMENT WITH SOFOSBUVIR

It is taken as a 400 mg tablet once only a day with or without food.

Below table is US Food and Drug Administration Approval:

Genotype	Medicines	Duration
Genotype 1 & 4	Sofosbuvir + Peg-interferon alfa +Ribavirin	12 weeks
Genotype 2	Sofosbuvir + Ribavirin	12 weeks
Genotype 3	Sofosbuvir + Ribavirin	24 weeks

Treatment with Sofosbuvir

Below table is European Medicines Agency Approval:

Genotype	Medicines	Duration
Genotype 1, 4, 5 & 6	Sofosbuvir + Peg-interferon alfa + Ribavirin	12 weeks
	Sofosbuvir + Ribavirin	24 weeks
Genotype 2	Sofosbuvir + Ribavirin	12 weeks
Genotype 3	Sofosbuvir + Peg-interferon alfa + Ribavirin	12 weeks
	Sofosbuvir + Ribavirin	24 weeks

Ledipasvir - US FDA

HCV Genotype and patient population	Medicine	Duration
Genotype 1 (Treatment-naive with or without cirrhosis)	ledipasvir+ sofosbuvir (Harvoni)	12 weeks (8 weeks can be considered in treatment-naive patients without cirrhosis who have pre-treatment HCV RNA less than 6 million IU/mL)
,Genotype 1 (Treatment-experienced without cirrhosis)	ledipasvir+ sofosbuvir (Harvoni)	12 weeks
Genotype 1 (Treatment-experienced with cirrhosis)	ledipasvir+ sofosbuvir (Harvoni)	24 weeks

Daclatasvir - European Medicines Agency

HCV Genotype and patient population	Medicines	Duration
Genotype 1 or 4 (without cirrhosis)	daclatasvir + sofosbuvir	12 weeks (Maybe prolong to 24 weeks for patients with prior treatment experience).
Genotype 1 or 4 (with compensated cirrhosis)	daclatasvir + sofosbuvir	24 weeks (Shortening treatment to 12 weeks may be considered for previously untreated patients with cirrhosis and positive prognostic factors such as IL28B CC genotype and/or low baseline viral load.) (Ribavirin may be added for patients with very advanced liver disease or with prior treatment experience.)
Genotype 3 (with compensated cirrhosis and/or treatment experienced)	daclatasvir + sofosbuvir + ribavirin	24 weeks
Genotype 4	daclatasvir + peginterferon alfa + ribavirin	24 weeks of daclatasvir in combination with 24-48 weeks of peginterferon alfa and ribavirin. (If the patient has HCV RNA undetectable at both treatment weeks 4 and 12, all 3 components of the regimen should be continued for a total duration of 24 weeks.) (If the patient achieves HCV RNA undetectable, but not at both treatment weeks 4 and 12, daclatasvir should be discontinued at 24 weeks and peginterferon alfa and ribavirin continued for a total duration of 48 weeks.)